SAB BIOTHERAPEUTICS, INC. (SABS) Free cash flow 2020–2025
SAB BIOTHERAPEUTICS, INC. (SABS) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$45.7MFY2025 · since FY2020: -$2.7M → -$45.7M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$45.7M | -32.0% |
| FY2024 | -$34.6M | -36.8% |
| FY2023 | -$25.3M | +1.2% |
| FY2022 | -$25.6M | -186.1% |
| FY2021 | -$9.0M | -228.5% |
| FY2020 | -$2.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SABS financial trends
SABS RevenueSABS Net incomeSABS Net marginSABS Gross profitSABS Gross marginSABS Operating incomeSABS Operating marginSABS Operating cash flowSABS Capital expendituresSABS Return on equitySABS Stock buybacksSABS Dividends paidSABS Total assetsSABS Total liabilitiesSABS Shareholders’ equitySABS overview →